Use and continuity of weight‐modifying medications among adults with diabetes and overweight/obesity: US population study
Authors' conclusion
Over 2010-2019, 64.9% of adults with diabetes and overweight/obesity were treated with WI medications, 13.5% with WR medications, and 73.1% with WN medications. Discontinuation of WR medications was nearly twice that of WI medications.
Study context
- Population
- US adults (≥18 years) with diabetes and BMI ≥27 kg/m² (≥25 kg/m² for Asians); mean age 60.0 years (SD 13), 50% female
- Participants
- 7,402 adults
- Exposure
- Weight-inducing (WI) vs weight-reducing (WR) vs weight-neutral (WN)
- Outcome
- Trends in use and continuity of use of diabetes-specific and non-diabetes WR, WI and WN medications
- Follow-up
- 2010-2019
Methodological detailspopulation-based, Medical Expenditure Panel Surveys 2010-2019
- Population-based
- Medical Expenditure Panel Surveys 2010-2019
Main finding
As reported in the abstract
Use of weight-modifying medications
| Group | Value | 2010 | 2019 | From | To | Fold increase | Range from | Range to |
|---|---|---|---|---|---|---|---|---|
| WI | 64.9% | 68.9% (95% CI: 64.3%-73.5%) | 58.6% (95% CI: 54.7%-62.5%) | |||||
| WR | 13.5% | 6.4% (95% CI: 4.1%-8.7%) | 21.2% (95% CI: 18.0%-24.4%) | 3.31 | ||||
| WN | 73.1% | 70.5% (95% CI: 66.5-74.6) | 75.0% (95% CI: 71.7%-78.4%) |
Value
WI64.9%
WR13.5%
WN73.1%
2010
WI68.9% (95% CI: 64.3%-73.5%)
WR— not stated in the abstract
WN— not stated in the abstract
2019
WI58.6% (95% CI: 54.7%-62.5%)
WR— not stated in the abstract
WN— not stated in the abstract
From
WI— not stated in the abstract
WR6.4% (95% CI: 4.1%-8.7%)
WN— not stated in the abstract
To
WI— not stated in the abstract
WR21.2% (95% CI: 18.0%-24.4%)
WN— not stated in the abstract
Fold increase
WI— not stated in the abstract
WR3.31
WN— not stated in the abstract
Range from
WI— not stated in the abstract
WR— not stated in the abstract
WN70.5% (95% CI: 66.5-74.6)
Range to
WI— not stated in the abstract
WR— not stated in the abstract
WN75.0% (95% CI: 71.7%-78.4%)
Observational data: associations, not effects.
Further findings
Discontinuation in second year among users of diabetes-specific medications in first year
First-year use
Original publication
Use and continuity of weight‐modifying medications among adults with diabetes and overweight/obesity: US population study. Obesity (Silver Spring). Published 2 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →